DeSantis Announces $60 Million in Florida Cancer Innovation Fund Awards

Gov. Ron DeSantis announced $60 million in awards through the Florida Cancer Innovation Fund at an event in Orlando on Aug. 19, joined by State Surgeon General Dr. Joseph Ladapo and Agency for Health Care Administration Secretary Shevaun Harris. With the awards announced, the fund's current cycle carries $70 million in total funding, roughly $10 million more than the prior cycle.

The Florida Cancer Innovation Fund directs state money toward cancer research projects at Florida institutions. It is one of several state programs built around the argument that Florida should be a center of cancer research and treatment rather than a place where patients travel elsewhere for care. Florida has one of the largest and oldest populations in the country, which makes cancer incidence a significant public health and fiscal issue for the state.

The announcement was made through the governor's office and the Agency for Health Care Administration. The state has not published a complete, itemized list of every award recipient in the materials circulated at the announcement, and details on individual project allocations typically follow in subsequent agency documentation.

The event also brought together three officials whose portfolios intersect on cancer care. The governor controls the appropriation. The surgeon general leads the Department of Health, which handles cancer registry data and screening programs. The Agency for Health Care Administration runs Florida Medicaid, which pays for a substantial share of cancer treatment in the state. Cancer policy in Florida runs through all three, and the coordination among them determines whether research money connects to patient care.

What the fund does

The Florida Cancer Innovation Fund was created to support research projects with the potential to advance cancer detection, treatment, and prevention. Awards go to institutions conducting the research rather than directly to patients, and the program is administered through state health agencies rather than through the university system alone.

Florida's cancer research infrastructure is concentrated in a handful of institutions. Moffitt Cancer Center in Tampa is the state's only National Cancer Institute-designated comprehensive cancer center. The University of Florida Health Cancer Center in Gainesville and the Sylvester Comprehensive Cancer Center at the University of Miami hold NCI designations as well. Additional research capacity sits at Mayo Clinic Florida in Jacksonville and at academic medical centers across the state.

State funding of this kind is meant to complement federal research dollars rather than replace them. Federal grants from the National Institutes of Health and the National Cancer Institute remain the dominant source of cancer research funding nationally, and state programs typically fund earlier-stage or state-specific work that helps institutions build toward larger federal awards.

National Cancer Institute designation is the credential that structures this landscape. It requires demonstrated research capacity, clinical trial infrastructure, and community outreach, and it is reviewed periodically rather than granted permanently. Comprehensive designation, which Moffitt holds, adds requirements for research spanning basic science, clinical work, and population health. Designation brings federal support and, more importantly, brings clinical trials, which is the mechanism by which patients gain access to treatments before they are broadly available.

Why the population math matters

Florida's demographics make cancer a distinctly large problem here. The state has more than 4.6 million residents aged 65 and older, one of the largest such populations in the country in absolute terms. Cancer incidence rises sharply with age, which means Florida's caseload is proportionally heavier than states with younger populations.

That has downstream effects on the state's health system and its budget. Medicaid, hospital capacity, oncology workforce supply, and rural access to treatment are all shaped by the volume of cancer cases. Rural counties in North Florida and the interior of the peninsula have limited local oncology services, and patients often travel substantial distances for treatment.

State officials have framed cancer research investment as both a health initiative and an economic development one. Research institutions attract federal funding, clinical trials, biotechnology employers, and specialist physicians. The argument is that a stronger research base makes Florida a place where oncologists and researchers build careers.

Skin cancer deserves specific mention in any Florida cancer discussion. The state's combination of intense year-round ultraviolet exposure, an outdoor-oriented population, and a large share of residents with lighter skin produces melanoma incidence rates that rank among the highest in the country. Melanoma is highly survivable when caught early and dangerous when it is not, which makes it one of the clearest cases where screening access and public awareness translate directly into outcomes.

The broader state health portfolio

The cancer announcement comes as Florida's health agencies are managing several other pressures. The state is in the middle of its largest measles outbreak in decades, with the Florida Department of Health reporting 155 cases so far in 2026 compared with seven in all of 2025. A cluster associated with Ave Maria University in Collier County accounts for a large share of the total.

Separately, community clinics in Florida that receive direct federal HIV prevention funding are scheduled to lose that funding in September following a federal decision not to renew a Centers for Disease Control and Prevention grant program for community-based organizations. Florida clinics receive roughly $26 million under that program, the second-largest amount of any state. Supplemental CDC funding is being routed to state health departments instead, with Florida anticipated to receive more than $11 million.

Those developments sit alongside the cancer announcement as part of a state health portfolio that is expanding in some areas while contracting in others. The state's surgeon general has drawn national attention for his positions on vaccination policy, and public health advocates have raised questions about how the department is prioritizing its resources.

Those three storylines, expanded cancer research funding, a growing measles outbreak, and contracting federal HIV prevention money, are occurring simultaneously and are not connected by any single policy decision. They do, however, land on the same agencies and compete for the same administrative attention. Public health departments operate with finite epidemiological and program staff, and a year with an active outbreak and a funding transition is a year in which those staff are stretched.

Where the money is likely to land

Based on how prior cycles of state cancer funding have been distributed, awards typically go to a mix of established research centers and to institutions building new capacity. The stated purpose of the fund is innovation, which in practice means projects at the earlier end of the research pipeline rather than routine clinical operations.

Institutions in the Orlando area have been building oncology research capacity in recent years, and the choice to hold the announcement in Orlando is consistent with a broader state effort to expand research beyond the traditional Tampa, Gainesville, and Miami concentration. Orlando Health and AdventHealth both operate substantial cancer programs in Central Florida.

For patients, the effect of research funding is indirect and slow. Research awards do not change what a treatment costs next month. What they can change over a period of years is whether a clinical trial is available in Florida, whether a specialist practice can be sustained locally, and whether new diagnostic approaches reach Florida patients early.

Rural access is the sharpest version of that question. A patient in a county without a local oncologist faces a choice between traveling for every appointment across a treatment course that can run months, or forgoing recommended care. Distance is a documented predictor of treatment completion and of outcomes. Research funding does not solve that directly, but institutions with strong research programs are the ones that build satellite clinics and telemedicine networks, which do.

How this fits the budget picture

The awards are drawn from state appropriations. Florida's Fiscal Year 2026-27 budget, signed at $114.5 billion, includes health and human services as the largest single spending category, driven primarily by Medicaid. Research funding of this scale is a small share of that total but a meaningful one within the state's discretionary health spending.

The next governor will inherit the program. Neither Byron Donalds nor David Jolly, the parties' nominees, has made cancer research funding a central campaign theme, and continuation of the fund at current levels would depend on future legislative appropriations rather than on any long-term commitment.

Property tax changes on the November ballot could also affect state and local fiscal capacity in ways that eventually reach discretionary programs, though the connection between Amendment 3 and state-level research funding is indirect.

Florida's overall fiscal position has been strong through recent budget cycles, supported by sales tax collections that benefit from both a growing population and a large tourism sector. That combination has allowed the Legislature to fund discretionary priorities without difficult tradeoffs. A slowdown in either population growth or visitor spending would change that arithmetic, and discretionary research funding is generally among the first categories examined when revenue tightens.

What's next

The Agency for Health Care Administration and the Florida Department of Health typically publish award details after an announcement of this kind, including recipient institutions and project descriptions. Those documents are the place to look for specifics on which projects received funding and at what levels.

Legislative committees will review the program during the 2027 session, which is when the next funding cycle would be set. Lawmakers have generally supported cancer research appropriations on a bipartisan basis, and the program has grown across recent cycles.

Floridians looking for cancer screening resources or clinical trial information can find them through the Florida Department of Health and through the NCI-designated centers at Moffitt, the University of Florida, and the University of Miami.

Patients seeking clinical trial options can search the federal ClinicalTrials.gov registry by condition and location, which lists trials operating at Florida institutions. Referral to a trial generally runs through a treating oncologist, and eligibility criteria are specific to each study. Florida's NCI-designated centers maintain their own trial listings as well.